Standard BioTools (LAB) Competitors

Transcat (NASDAQ:TRNS) and Standard BioTools (NASDAQ:LAB) are both small-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Does the MarketBeat Community believe in TRNS or LAB?

Transcat received 205 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 66.88% of users gave Transcat an outperform vote.

Company	Underperform	Outperform
Transcat	Outperform Votes 210 66.88%	Underperform Votes 104 33.12%
Standard BioTools	Outperform Votes 5 100.00%	Underperform Votes No Votes

Is TRNS or LAB more profitable?

Transcat has a net margin of 6.63% compared to Standard BioTools' net margin of -79.92%. Transcat's return on equity of 7.36% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	6.63%	7.36%	5.90%
Standard BioTools	-79.92%	-27.05%	-15.52%

Does the media prefer TRNS or LAB?

In the previous week, Transcat had 1 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for Transcat and 3 mentions for Standard BioTools. Transcat's average media sentiment score of 1.60 beat Standard BioTools' score of 0.83 indicating that Transcat is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Standard BioTools	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, TRNS or LAB?

Transcat has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in TRNS or LAB?

98.3% of Transcat shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 2.3% of Transcat shares are owned by company insiders. Comparatively, 53.1% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has preferable valuation and earnings, TRNS or LAB?

Transcat has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$270.61M	3.54	$13.65M	$1.98	52.60
Standard BioTools	$155.90M	4.24	-$74.66M	-$0.71	-2.50

Do analysts rate TRNS or LAB?

Transcat presently has a consensus target price of $130.25, suggesting a potential upside of 25.06%. Standard BioTools has a consensus target price of $2.88, suggesting a potential upside of 61.84%. Given Standard BioTools' stronger consensus rating and higher possible upside, analysts clearly believe Standard BioTools is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Standard BioTools	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Transcat beats Standard BioTools on 12 of the 18 factors compared between the two stocks.